Page 64 - Read Online

Chan et al. Hepatoma Res 2018;4:5 I http://dx.doi.org/10.20517/2394-5079.2017.49 Page 17 of 17

J Clin Oncol 2013;31:3647-55.
128. Lao XM, Luo G, Ye LT, Luo C, Shi M, Wang D, Guo R, Chen M, Li S, Lin X, Yuan Y. Effects of antiviral therapy on hepatitis B virus
reactivation and liver function after resection or chemoembolization for hepatocellular carcinoma. Liver Int 2013;33:595-604.
129. Kim JH, Park JW, Kim TH, Koh DW, Lee WJ, Kim CM. Hepatitis B virus reactivation after three-dimensional conformal radiotherapy in
patients with hepatitis B virus-related hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2007;69:813-9.
130. Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Yamazaki O, Shiomi S, Tamori A, Oka H, Igawa S, Kuroki T, Kinoshita H. Effects
of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular
carcinoma. A randomized, controlled trial. Ann Intern Med 2001;134:963-7.
131. Mazzaferro V, Romito R, Schiavo M, Mariani L, Camerini T, Bhoori S, Capussotti L, Calise F, Pellicci R, Belli G, Tagger A, Colombo M,
Bonino F, Majno P, Llovet JM; HCC Italian Task Force. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver
resection in HCV cirrhosis. Hepatology 2006;44:1543-54.
132. Conti F, Buonfiglioli F, Scuteri A, Crespi C, Bolondi L, Caraceni P, Foschi FG, Lenzi M, Mazzella G, Verucchi G, Andreone P, Brillanti
S. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol
2016;65:727-33.
133. Reig M, Marino Z, Perello C, Inarrairaegui M, Ribeiro A, Lens S, Diaz A, Vilana R, Darnell A, Varela M, Sangro B, Calleja JL, Forns X,
Bruix J. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol
2016;65:719-26.
134. Verslype C, Cohn AL, Kelley RK, Yang TS, Su WC, Ramies DA, Lee Y, Shen X, Cutsem EV. Activity of cabozantinib (XL184) in
hepatocellular carcinoma: results from a phase II randomized discontinuation trial (RDT). J Clin Oncol 2012;30 Suppl 15:4007.
135. Kobayashi S, Ueshima K, Moriguchi M, Takayama T, Izumi N, Yoshiji H, Hino K, Oikawa T, Chiba T, Motomura K, Kato J, Yasuchika
K, Ido A, Kinoshita J, Sato T, Ikeda M, Okusaka T, Kudo M, Tamura K, Furuse J. JET-HCC: a phase 3 randomized, double-blind,
placebo-controlled study of tivantinib as a second-line therapy in patients with c-Met high hepatocellular carcinoma. Ann Oncol
2017;28:mdx369.003.